Outcomes in post-acute sequelae of COVID-19 (PASC) at 6 months post-infection part 1: cognitive functioning. Whiteside D.M., Basso M.R., Naini S.M., Porter J., Holker E., Waldron E.J., et al. Diagnosing, as well as the guidance and treatment of dementia, including Behavioural and Psychological Symptoms of Dementia (BPSD), is often done in old age psychiatry which, at least in the Netherlands, make up to 25 of all memory clinics (Verhey et al., Citation 2010). Neurocognitive profiles in patients with persisting cognitive symptoms associated with covid-19. Background: The Montreal Cognitive Assessment (MoCA) is a popular cognitive screening tool used in stroke, but lacks sensitivity for detecting impairment in stroke-relevant domains of processing speed, non-verbal memory and executive functions. Krishnan K., Miller A.K., Reiter K., Bonner-Jackson A. Cognitive impairment after covid-19-a review on objective test data. An Italian multicenter retrospective-prospective observational study on neurological manifestations of covid-19 (NEUROCOVID) Neurol Sci. įerrarese C., Silani V., Priori A., Galimberti S., Agostoni E., Monaco S., et al. Therefore, patients with persistent cognitive complaints in the setting of PASC who score in the normal range on the MoCA should be referred for formal NP assessment.ĬOVID-19 Cognitive deficits Montreal cognitive assessment Neuropsychological testing “Brain fog”.Ĭopyright © 2022 Elsevier Inc. The MoCA may not be accurate for detecting neither mild nor more severe degrees of diminished NP test performance in PASC. The MoCA had an accuracy of 63.3% at detecting any degree of diminished NP performance, and an accuracy of 73.3% at detecting extremely low NP performance. MoCA score was inversely correlated with fatigue and depression measures and ethnic minority participants scored on average lower, despite similar education and estimated premorbid function. The overall sample had a mean score of 26.1 on the MoCA, with approximately one third screening below the cutoff score of 26, similar to the rate of extremely low NP test performance. Background: The Montreal Cognitive Assessment (MoCA) is a cognitive screening tool known to accurately measure mild cognitive impairment (MCI) in many different neurological populations. Sixty participants underwent neuropsychological, psychiatric, and medical assessments, as well as the Montreal Cognitive Assessment, 6-8 months after acute COVID-19 infection. Montreal Cognitive Assessment (MoCA) is one of the most widely used cognitive screening tests in primary and secondary care globally. To determine the utility of the MoCA to screen for cognitive impairment in PASC. The Montreal Cognitive Assessment (MoCA) has been used to estimate prevalence of cognitive impairment in many studies of PASC, and is commonly employed as a screening test in this population, however, its validity has not been established. Appropriate cutoffs and point adjustments for education are suggested.Ĭross-cultural Montreal Cognitive Assessment dementia mild cognitive impairment.Cognitive complaints are one of the most frequent symptoms reported in post-acute sequelae of COVID-19 (PASC). The review highlights the necessity for cross-cultural considerations when using the MoCA, and recognizing it as a screen and not a diagnostic tool. Poor methodological rigor appears to have affected reported accuracy and validity of the MoCA. The results showed a wide range in suggested cutoffs for MCI cross-culturally, with variability in levels of sensitivity and specificity ranging from low to high. It was validated in the setting of mild cognitive impairment (MCI), and has subsequently been adopted in numerous other clinical settings. 1 It was created in 1996 by Ziad Nasreddine in Montreal, Quebec. Quality ratings, forest plots of validated studies (sensitivity and specificity) with covariates (suggested cut-offs, age, education and country), and summary receiver operating characteristic curve are presented. The Montreal Cognitive Assessment ( MoCA) is a widely used screening assessment for detecting cognitive impairment. The subject of the review assumes heterogeneity and therefore meta-analyses was not conducted. In addition, we report findings for differentiating dementias from NC and MCI from dementias, however, these were not considered to be an appropriate use of the MoCA. This review sourced a wide range of studies including case-control studies. Exempted from mandatory certification: Neuropsychologists and clinicians who have completed 1-year post-doc cognitive fellowship. We aimed to interrogate the validity of the MoCA in a cross-cultural context: in differentiating MCI from normal controls (NC) and identifying cut-offs and adjustments for age and education where possible. While there are many available versions, the cross-cultural validity of the assessment has not been explored sufficiently. The Montreal Cognitive Assessment (MoCA) is widely used to screen for mild cognitive impairment (MCI).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |